Sigilon Therapeutics Inc
SGTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.22M
Close$
Share Statistics
| Market cap | $56.22 Million |
|---|---|
| Enterprise Value | $57.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 4.11 |
| Outstanding Shares | 32,467,382 |
Return
| Return on Equity | -107.75% |
|---|---|
| Return on Assets | -53.23% |
| Return on Invested Capital | -100.03% |
Valuation & Multiples
| P/E Ratio | -16.76 |
|---|---|
| PEG | 34.35 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.27 |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | 0.77 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sigilon Therapeutics Inc
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial pr...